More on TEVA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $32.95 |
|
|||
| Open | $32.52 | ||||
| 52 Wk High | $66.55 | ||||
| 52 Wk Low | $37.82 | ||||
| Day High | $32.81 | ||||
| Day Low | $32.14 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,231,282 | ||||
- Teva lawsuit against Eli Lilly over Forteo revived by appeals court
- Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials
- UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
- Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.
- Form 4 TEVA PHARMACEUTICAL INDU For: Jun 18 Filed by: Shields Matthew
- Teva submits NDA for ecopipam to treat pediatric Tourette syndrome
- Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
- Form 144 TEVA PHARMACEUTICAL INDU Filed by: Shields Matthew
- Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew
- Form 4 TEVA PHARMACEUTICAL INDU For: Jun 11 Filed by: Kalif Eliyahu Sharon
Entities mentioned with TEVA
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Citi | View Related Stories »
- Options | View Related Stories »
- JPMorgan | View Related Stories »
- Barclays | View Related Stories »
- Morgan Stanley | View Related Stories »
- Show More...
